<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Dapsone, used for Pneumocystis jiroveci (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCP</z:e>) prophylaxis, is associated with increased risk of <z:hpo ids='HP_0012119'>methemoglobinemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Absence of <z:chebi fb="0" ids="38553">cytochrome b5</z:chebi> reductase enzyme activity causes congenital <z:hpo ids='HP_0012119'>methemoglobinemia</z:hpo>, but its role in dapsone-associated <z:hpo ids='HP_0012119'>methemoglobinemia</z:hpo> is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>The authors sought to elucidate drug-related risk factors for dapsone-associated <z:hpo ids='HP_0012119'>methemoglobinemia</z:hpo> in pediatric <z:hpo ids='HP_0002664'>oncology</z:hpo> patients, including contribution of <z:chebi fb="0" ids="38553">cytochrome b5</z:chebi> reductase enzyme activity </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Among 167 pediatric patients treated for <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> or <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> who received dapsone for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCP</z:e> prophylaxis, demographic and dapsone treatment data were retrospectively collected </plain></SENT>
<SENT sid="4" pm="."><plain>Drug-related risk factors were evaluated by Cox proportional hazards, and in a cross-sectional subgroup of 40 patients, <z:chebi fb="0" ids="38553">cytochrome b5</z:chebi> reductase enzyme activity was assessed </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:hpo ids='HP_0012119'>Methemoglobinemia</z:hpo> (median methemoglobin level = 9.0% [3.5-22.4]) was documented in 32 (19.8%) patients </plain></SENT>
<SENT sid="6" pm="."><plain>There was a 73% risk reduction in <z:hpo ids='HP_0012119'>methemoglobinemia</z:hpo> with dosing ≥20% below the target dose of 2 mg/kg/d (hazard ratio [HR], 0.27; 95% confidence interval [CI], 0.09-0.78; P = .016), whereas <z:hpo ids='HP_0012119'>methemoglobinemia</z:hpo> risk was increased with dosing ≥20% above the target dose (HR, 6.25; 95% CI, 2.45-15.93; P &lt; .001) </plain></SENT>
<SENT sid="7" pm="."><plain>Sex, body mass index, and age were not associated with increased risk </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="38553">Cytochrome b5</z:chebi> reductase enzyme activity did not differ by <z:hpo ids='HP_0012119'>methemoglobinemia</z:hpo> status (median 8.6 IU/g <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> [Hb]; [5.5-12.1] vs 9.1 IU/g Hb; [6.7-12.7]) </plain></SENT>
<SENT sid="9" pm="."><plain>No patient developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCP</z:e> on dapsone </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0012119'>Methemoglobinemia</z:hpo> occurred in almost 20% of pediatric <z:hpo ids='HP_0002664'>oncology</z:hpo> patients receiving dapsone for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCP</z:e> prophylaxis </plain></SENT>
<SENT sid="11" pm="."><plain>Higher dapsone dosing is associated with increased risk </plain></SENT>
<SENT sid="12" pm="."><plain>A cross-sectionally acquired <z:chebi fb="0" ids="38553">cytochrome b5</z:chebi> reductase enzyme activity level was not associated with <z:hpo ids='HP_0012119'>methemoglobinemia</z:hpo> risk </plain></SENT>
<SENT sid="13" pm="."><plain>Studies are needed to define biologic correlates of <z:hpo ids='HP_0012119'>methemoglobinemia</z:hpo> and evaluate lower dapsone doses for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PCP</z:e> prophylaxis </plain></SENT>
</text></document>